Abstract: The present invention relates to a novel lysyl oxidase genes, termed EER-7. The invention relates to the protein and nucleic acids encoding the protein. The invention further relates to an assay system to identify compounds that selectively modulate EER-7 protein activity by interaction with estrogen receptors.

Abstract: Methods and pharmaceutical compositions of use in regulation of mammalian bone-forming activities of SFRPs (secreted frizzled-related proteins) are disclosed. SFRPs are secreted receptors for Wnts, which are important polypeptide growth factors that are known to regulate fundamental biological processes such as tissue polarity, embryonic development, and tumorigenesis. Methods can be used to identify compounds which target the Wnt-antagonizing function of an SFRP by way of one or more domains or specific amino acids. Pharmaceutical compositions can be prepared using these compounds, and bone disorders can be treated using these pharmaceutical compositions.

Abstract: The present invention relates to a Wnt-Frizzled chimera. The present invention also relates to pharmaceutical compositions that can be screened or developed using Wnt-Frizzled chimeras. The methods and pharmaceutical compositions of the present invention can be used to treat bone disorders and cancer.

Abstract: The present invention provides isolated nucleic acids encoding full-length human estrogen receptor-? (hER?), which comprises 530 amino acids. The invention also provides isolated hER? polypeptides and hER?-reactive antibodies, including those that specifically recognize amino acids 1–45 of hER?. The invention also encompasses methods for identifying hER?-interactive compounds, including agonists, antagonists, and co-activators.

Abstract: The present invention provides isolated nucleic acids encoding full-length human estrogen receptor-? (hER?), which comprises 530 amino acids. The invention also provides isolated hER? polypeptides and hER?-reactive antibodies, including those that specifically recognize amino acids 1-45 of hER?. The invention also encompasses methods for identifying hER?-interactive compounds, including agonists, antagonists, and co-activators.

Abstract: The present invention provides isolated nucleic acids encoding full-length human estrogen receptor-&bgr; (hER&bgr;), which comprises 530 amino acids. The invention also provides isolated hER&bgr; polypeptides and hER&bgr;-reactive antibodies, including those that specifically recognize amino acids 1-45 of hER&bgr;. The invention also encompasses methods for identifying hER&bgr;-interactive compounds, including agonists, antagonists, and co-activators.

Abstract: The present invention relates to a novel lysyl oxidase genes, termed EER-7. The invention relates to the protein and nucleic acids encoding the protein. The invention further relates to an assay system to identify compounds that selectively modulate EER-7 protein activity by interaction with estrogen receptors.

Abstract: The present invention relates to a novel lysyl oxidase genes, termed EER-7. The invention relates to the protein and nucleic acids encoding the protein. The invention further relates to an assay system to identify compounds that selectively modulate EER-7 protein activity by interaction with estrogen receptors.